A Trial of Single Agent Axitinib as Maintenance Therapy for Patients With First Line Metastatic Colorectal Cancer (mCRC)

ClinicalTrials.gov ID: NCT01490866

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT01490866. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 14, 2026, 6:12 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase II Trial of Single Agent Axitinib as Maintenance Therapy for Patients With First Line Metastatic Colorectal Cancer (mCRC)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a non-randomized, open-label, Phase II trial investigating axitinib as a single-agent maintenance therapy following standard first-line FOLFOX/bevacizumab therapy for patients with mCRC.

Study identification

NCT ID: NCT01490866
Recruitment status: Completed
Study type: Interventional
Phase: Phase 2
Lead sponsor: SCRI Development Innovations, LLC; Other
Enrollment: 70 participants

Conditions and interventions

Conditions

Colorectal Cancer

Interventions

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jan 2012 (Type not available)
Primary completion: Jul 2015 (Actual)
Completion: Jul 2015 (Actual)
Last update posted: Sep 24, 2019

2012 – 2015

United States locations

U.S. sites: 12
U.S. states: 9
U.S. cities: 12

Facility	City	State	ZIP	Site status
NEA Baptist Clinic	Jonesboro	Arkansas	72401	—
Florida Cancer Specialists-South	Fort Myers	Florida	33916	—
Woodlands Medical Specialists	Pensacola	Florida	32503	—
Florida Cancer Specialists-North	St. Petersburg	Florida	33705	—
Northeast Georgia Medical Center	Gainesville	Georgia	30501	—
Oncology Hematology of SW Indiana	Newburgh	Indiana	47630	—
Hope Cancer Center	Terre Haute	Indiana	47802	—
Grand Rapids Oncology Program	Grand Rapids	Michigan	49503	—
Nebraska Methodist Hospital	Omaha	Nebraska	68114	—
Atlantic Health System	Summit	New Jersey	07901	—
Tennessee Oncology	Nashville	Tennessee	37203	—
Texas Health Physician Group	Dallas	Texas	75243	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT01490866, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Sep 24, 2019 · Synced Nov 14, 2026